MedTrace Logo

Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study

NCT07287137 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2026-05-04

No results posted yet for this study

Summary

CIRV2 is a Phase IV randomized, open-label, trial of FDA-approved COVID-19 and/or influenza vaccines (no more than minimal risk) with longitudinal follow-up. In 2025 CIRV2 will compare immunogenicity and reactogenicity of the recombinant Novavax COVID-19 vaccine and the mRNA Pfizer-BioNTech COVID-19 vaccine.

Conditions

  • COVID -19
  • COVID - 19
  • COVID 19
  • Influenza
  • Respiratory Virus
  • Respiratory Viruses
  • Respiratory Virus Infection
  • Respiratory Virus Infections

Interventions

DRUG

Pfizer-BioNTech mRNA COVID-19 vaccine

COVID-19 Vaccine, mRNA

DRUG

Novavax recombinant protein vaccine

Recombinant protein vaccine

Sponsors & Collaborators

Principal Investigators

  • Edward Mitre, MD · Uniformed Services University of the Health Sciences

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-11-12
Primary Completion
2027-09-30
Completion
2027-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07287137 on ClinicalTrials.gov